About CELLMED

CELLMED is reshaping the future of cancer treatment by focusing on the clinical development of its lead product PROCURE®. By supporting the rise of personalized medicine and cellular immunotherapy CELLMED aims to provide a better treatment for patients.
Important criteria for dendritic cell therapy have been recently identified and established providing for the reduced risk and significant upside potential for CELLMED. Autologous cell therapy has almost no side effects but a very complicated mechanism of action. Many mistakes were made previously, resulting in ambiguous clinical data concerning dendritic cell vaccine efficacy as a treatment for cancer and notable corporate failures. Early clinical results suggest CELLMED’s science has overcome these prior errors and its phase IIb protocols will provide stronger evidence of such.

CELLMED is reshaping the future of cancer treatment by focusing on the clinical development of its lead product PROCURE®. By supporting the rise of personalized medicine and cellular immunotherapy CELLMED aims to provide a better treatment for patients.
Important criteria for dendritic cell therapy have been recently identified and established providing for the reduced risk and significant upside potential for CELLMED. Autologous cell therapy has almost no side effects but a very complicated mechanism of action. Many mistakes were made previously, resulting in ambiguous clinical data concerning dendritic cell vaccine efficacy as a treatment for cancer and notable corporate failures. Early clinical results suggest CELLMED’s science has overcome these prior errors and its phase IIb protocols will provide stronger evidence of such.

The Technology PROCURE®

The product PROCURE® is a vaccine manufactured from cells isolated from the individual patients.

Dentritic cell therapy

A unique double loaded dendritic cell therapy for the treatment of all solid tumors.

The Loading

Two universal tumor antigens, pivotal for development of most tumor types, maximize efficacy and minimize side effects.

Effects on immune system

Both arms of the immune system are directly activated without restrictions proven by striking phase I/IIa results.

IP

Patents are granted in the EU and Japan and pending in the US.

Platform technology

PROCURE® is designed for a broad spectrum of therapeutic indications.

Manufacturing

Robust and of reproducible high quality with off the shelf antigens and potency release assay.

Clinical Development

Clinical objective with the product PROCURE® is to delay relapse and to control metastases. Results of the completed clinical phase I/IIa trial have shown very promising results for safety and efficacy in ovarian cancer. These results are supported by highly significant immune data.

Clinical Phase I/IIa with PROCURE®

Clinical objective with the product PROCURE® is to delay relapse and to control metastases. Results of the completed clinical phase I/IIa trial have shown very promising results for safety and efficacy in ovarian cancer. These results are supported by highly significant immune data.

Clinical Phase I/IIa with PROCURE®

Design

15 ovarian cancer patients randomized in two treatment arms to confirm the safety and immunological proof of concept of PROCURE®

Results

  • confirmed product safety
  • specific T cell responses exhibit a striking 100% rate of positive immune responses with high significance
  • Cancer recurrence delayed by >163% compared to historical control (interim data)

Now a phase IIb trial with the product to start as soon as possible after the availability of phase IIb funding is scheduled. Results with time to progression as primary endpoint are expected 41 months after funding.

Now a phase IIb trial with the product to start as soon as possible after the availability of phase IIb funding is scheduled. Results with time to progression as primary endpoint are expected 41 months after funding.

Team

GERHARD HUBER, PHD

Chief Executive Officer

 

Dr. Huber has extensive experience with start up companies and was involved with the company since its inception. He has a strong background in leading negotiations and brings an extensive network of contacts to the table.

KARL KRISTA, MD, MBA

Chief Scientific Officer

 

He has not only managerial expertise from his years at McKinsey but also a unique track record in the development of cancer vaccines and ovarian cancer treatment.

Investors

The company is financed by private investors.

Up to now, about USD 15.5 million in equity has been invested in the project.

3 reasons why CELLMED is a great investment opportunity:

  • Unique dendritic cell therapy with promising clinical results
  • Solid and well-controlled manufacturing process with potential for automation
  • Ready for further clinical development

Contact us

office@cellmed-science.com







captcha